PUBLISHER: Grand View Research | PRODUCT CODE: 1701642
PUBLISHER: Grand View Research | PRODUCT CODE: 1701642
The global plastics in personalized drug delivery systems market size is anticipated to reach USD 3.59 billion by 2030, registering a CAGR of 10.79% from 2025 to 2030, according to a new report by Grand View Research, Inc. The plastics in personalized drug delivery systems industry is a crucial segment of the global healthcare and pharmaceutical industry, driven by the need for advanced, patient-centric drug delivery solutions. Polymers such as PLA, PLGA, and PEG-based hydrogels are increasingly being utilized to enhance drug stability, bioavailability, and controlled release mechanisms. These materials offer superior biocompatibility, tunable degradation rates, and targeted drug delivery capabilities, making them indispensable in applications ranging from nanoparticle-based injectables to bioresorbable implants. The rising adoption of precision medicine, fueled by advancements in biotechnology and material sciences, is further accelerating the demand for specialized polymeric drug carriers, ensuring improved
therapeutic outcomes and patient adherence.
A key driver for market growth is the expanding role of polymer-based drug carriers in chronic disease management. With the increasing prevalence of cancer, diabetes, and neurological disorders, the demand for long-acting injectable therapies and localized drug delivery systems is surging. Plastics provide highly customizable properties, enabling the development of stimuli-responsive, pH-sensitive, and temperature-controlled drug release platforms. Moreover, regulatory approvals for biodegradable and bioabsorbable polymers have led to a wider acceptance of polymer-based drug delivery innovations. As leading pharmaceutical firms invest in smart polymeric formulations and biotech startups pioneer next-generation drug delivery technologies, the market for plastics in personalized drug delivery systems is poised for significant expansion, shaping the future of precision therapeutics.
The market players are focusing on various strategic initiatives such as mergers, acquisitions, and collaborations. For instance, in February 2024, Glenmark Pharmaceuticals launched Polyethylene Glycol 3350 Powder for Solution, an over-the-counter osmotic laxative, in the US market.